All Stories
Follow
Subscribe to Marseille-Kliniken AG

Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Quarterly or Semiannual Financial Statements
- Sales increased to EUR 152.1 million after three quarters - More and more positive signs from the Rehabilitation division - Full-year earnings expected to improve compar

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
09.05.2005
In the first three quarters of the fiscal year 2004/05, the
Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was
able to further increase sales by 1.2% to EUR 152.1 million (previous
year EUR 150.3 million). The earnings pursuant to DVFA/SG (IFRS)
amounted to EUR 6.4 million compared with EUR 6.2 million in the
previous year. The earnings per share came to EUR 0.53 following EUR
0.51 in the same period one year ago. Thus, due to its strong
earnings power the Nursing division was also able to more than offset
the decline in earnings in Rehabilitation in the third quarter of the
business year 2004/2005.
The occupancy rate in the entire Group amounted to 89.3% for the
reference period compared with 89.8% one year ago. In addition to the
still low utilization rate of the Rehabilitation division, the main
reasons are start-up facilities in the Nursing segment.
In its core segment Nursing, in which Marseille-Kliniken provides
three quarters of the Group’s total bed capacity, sales and earnings
continued to improve. With sales of EUR 111.3 million in this segment
during the period under review, Marseille-Kliniken realized a rise in
sales of EUR 3 million with respect to the EUR 108.3 million sales
generated in the same period one year ago. The earnings pursuant to
DVFA/SG (IFRS) once again improved compared with the prior year after
the completion of modernization measures. It rose to EUR 9.3 million,
up EUR 0.7 million from EUR 8.6 million in the previous year.
There are more and more signs of normalization in the Rehabilitation
segment. Even though the division’s sales and earnings were burdened
because of restructuring measures, the important key figure for the
sector, the utilization rate, improved from 74% to 75.8%. As
expected, sales of EUR 39.1 million in the first nine months of the
fiscal year 2004/05 were EUR 2.9 million below previous year's level
of EUR 42.0 million. The earnings pursuant to DVFA/SG (IFRS) of EUR
-2.9 million were still below last year's amount of EUR -2.4 million.
However, during the 3rd quarter the loss contribution was reduced by
EUR 365,000 (23%) to EUR 1.215 million compared with the same period
one year ago.
The so far solid development will continue in the remaining three
months. Therefore, we expect the growth in the Nursing division and
the beginning recovery in the Rehabilitation segment to result in a
disproportionately high increase in the DVFA result for the entire
business year 2004/2005 (previous year: EUR 7.9 million).
end of announcement                    euro adhoc 09.05.2005 07:22:44 

Further inquiry note:

Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401

as well as
Hillermann Consulting
Christian Hillermann
Managing Director
Eppendorfer Baum 5
20249 Hamburg
Tel.: +49 40 / 414069-13
Fax: +49 40 / 414069-14

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen: Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bremer Wertpapierbörse (BWB) / free trade
Hamburger Wertpapierbörse / official dealing
Frankfurter Wertpapierbörse / official dealing

Original content of: Marseille-Kliniken AG, transmitted by news aktuell

More stories: Marseille-Kliniken AG
More stories: Marseille-Kliniken AG